Brian M. Slomovitz, MD, Florida International University
Articles
Future of Advanced Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Novel Targets for Advanced Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Endometrial Cancer: Chemo-Free Regimens on the Horizon
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Emerging Agents: Treatment of Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Sequencing for Advanced Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Recurrent Endometrial Cancer: Safety of Combination Therapy
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Combination Therapy for Recurrent Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Emerging ICI Therapy for Advanced Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Immune Checkpoint Inhibitors in Advanced Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
GOG-258 and PORTEC-3 Studies in Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
GOG-249 Study in Early-Stage Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
GOG 0209 Study in Advanced Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Role of Biomarker Testing in Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Risk Classification of Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Overview of Endometrial Cancer
Bradley J. Monk, MD, FACS, FACOG, Arizona Oncology;Kathleen N. Moore, MD, University of Oklahoma;David M. O'Malley, MD, The Ohio State University;Brian M. Slomovitz, MD, Florida International University;Krishnansu S. Tewari, MD, University of California, Irvine
January 4th 2021Read More
Latest Updated Articles
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Medical Oncologists: The Show and After Show
Published: October 30th 2024 | Updated: November 7th 2024
Phase 1/2 ALKOVE-1 Study of NVL-655 in ALK-positive (ALK+) Solid Tumors
Published: October 18th 2024 | Updated: October 21st 2024
Updated Efficacy and Safety From the Phase 2 PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic NSCLC (mNSCLC)
Published: October 14th 2024 | Updated: October 16th 2024
Daratumumab + Bortezomib/Lenalidomide/Dexamethasone in Patients With Transplant-ineligible or Transplant-deferred Newly Diagnosed Multiple Myeloma: Results of the Phase 3 CEPHEUS Study
Published: September 27th 2024 | Updated: October 9th 2024
Petosemtamab Plus Pembrolizumab vs. Pembrolizumab Alone for First-Line (1L) Treatment of Recurrent/Metastatic (R/M) PD-L1–Positive Head and Neck Squamous Cell Carcinoma (HNSCC): A Randomized, Open-Label, Phase 3 Trial
Published: September 30th 2024 | Updated: October 4th 2024
Pooled Efficacy and Safety From 2 Pivotal Phase 2 Trials of Taletrectinib in Patients With Advanced or Metastatic ROS1+ Non–Small Cell Lung Cancer
